Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938886 · ClinicalTrials.gov registry record · Phase 2
Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
A Phase 2 study of Cigarette Smoking and Hazardous Drinking, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00938886: Completed Phase 2 study of Cigarette Smoking and Hazardous Drinking, sponsored by Brown University.
NCT00938886 is a Phase 2 study of Cigarette Smoking and Hazardous Drinking that has completed, run by Brown University. The registered enrollment target is 150 participants, below the 173-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00938886, a Phase 2 study of Cigarette Smoking and Hazardous Drinking, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking cessation outcomes in heavy drinkers seeking smoking cessation treatment.
Primary Outcome
Defined for women as percent of days drinking 4 or more drinks in a day. For men, percent of days drinking 5 or more drinks in a day
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone
Study Locations (1)
Rhode Island
- Brown University - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT00938886 record still lists
NCT00938886 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 173-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (13% lower).
The record links to 2 conditions, with Cigarette Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00938886 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00938886 about?
NCT00938886 is a clinical study titled "Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment". To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking cessation outcomes in heavy drinkers seeking smoking cessation treatment.
What is the current status of trial NCT00938886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2009-10. Estimated completion is 2015-12.
What conditions does trial NCT00938886 study?
This clinical trial studies the following conditions: Cigarette Smoking, Hazardous Drinking.
What interventions are being tested in trial NCT00938886?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00938886?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00938886 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00938886's enrollment target sits among peer trials
150 19th of 45 higher than 26 of 45 other Cigarette Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cigarette Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
RECRUITING · Phase 2
-
Semaglutide for Post-Smoking Cessation Weight Management
RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
-
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia